Table 2.
Baseline clinical and biochemical characteristics of 162 type 2 diabetic patients whose kidney function deteriorated and did not deteriorate over a 6.0-year follow-up.
| Deterioration | p values | ||
|---|---|---|---|
| Present (n = 40) | Absent (n = 122) | ||
| Male sex (n, %) | 21, 53 | 68, 56 | 0.72 |
| Smokers (n, %) | 14, 35 | 39, 32 | 0.75 |
| Age (years) | 66 ± 10 | 61 ± 10 | 0.01 |
| BMI (kg/m2) | 24.6 ± 3.1 | 24.1 ± 3.9 | 0.52 |
| Waist circumference (cm) | 87.9 ± 7.8 | 86.7 ± 10.6 | 0.52 |
| Duration of diabetes (years) | 10.6 ± 8.1 | 9.4 ± 7.0 | 0.35 |
| Treatment of diabetes; diet/OHA/insulin (n, %) | 12/21/7, 30/53/18 | 41/60/21, 34/49/17 | 0.91 |
| Hypertension; CCB/RASi/diuretics (n, %) | 17/16/3, 43/40/8 | 39/52/4, 32/43/3 | 0.41 |
| HbA1c (%) | 7.1 ± 0.8 | 7.0 ± 0.9 | 0.42 |
| Fasting PG (mg/dL) | 125 ± 22 | 125 ± 23 | 0.97 |
| Postbreakfast PG (mg/dL) | 155 ± 44 | 154 ± 50 | 0.87 |
| CV-HbA1c (%) | 7.9 ± 5.7 | 6.4 ± 5.7 | 0.15 |
| Total cholesterol (mg/dL) | 188 ± 21 | 188 ± 21 | 0.998 |
| LDL cholesterol (mg/dL) | 112 ± 22 | 111 ± 22 | 0.92 |
| HDL cholesterol (mg/dL) | 53 ± 14 | 56 ± 16 | 0.28 |
| Fasting TG (mg/dL) | 127 ± 55 | 110 ± 49 | 0.06 |
| Postbreakfast TG (mg/dL) | 158 ± 70 | 141 ± 59 | 0.17 |
| Serum creatinine (mg/dL) | 0.8 ± 0.2 | 0.7 ± 0.2 | 0.07 |
| eGFR (mL/min/1.73 m2) | 69 ± 14 | 78 ± 17 | 0.004 |
| ΔeGFR (mL/min/1.73 m2/year) | −3.1 ± 2.9 | −0.5 ± 2.7 | 0.000 |
| Uric acid (mg/dL) | 5.6 ± 1.5 | 5.1 ± 1.2 | 0.048 |
| Systolic BP (mmHg) | 131 ± 10 | 128 ± 12 | 0.17 |
| CV-systolic BP (%) | 8.1 ± 2.3 | 8.0 ± 2.2 | 0.82 |
| Diastolic BP (mmHg) | 72 ± 6 | 72 ± 7 | 0.85 |
| Urinary ACR (mg/g) | 223 ± 624 | 41 ± 89 | 0.002 |
| log ACR | 1.5 ± 0.6 | 1.2 ± 0.5 | 0.013 |
| Leucocyte count (103/μL) | 6.2 ± 1.4 | 5.7 ± 1.5 | 0.046 |
| Maximum IMT (mm) | 1.1 ± 0.3 | 1.0 ± 0.3 | 0.03 |
| Mean IMT (mm) | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.02 |
| ACR ≥ 30 mg/g (n, %) | 17, 43 | 36, 30 | 0.13 |
Mean ± SD or n, %. Abbreviations are the same as in Table 1.